Determination of Phenytoin and Its Major Metabolite, 5-(p-Hydroxyphenyl)-5-phenylhydantoin in Urine by High-Performance Liquid Chromatography

Bahal, Neeta; Nahata, Milap C.

doi:10.1080/10826079308019576

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bahal and Nahata (1993) 17 was described a new method for determination of both phenytoin and its major metabolite, 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) in urine. In this method, a Water 10 μm μBondapak C-18 column was used in the sample extraction step, a mobile phase containing 45% acetonitrile and 55% distilled water was used in the seperation, and the ultraviolet detector set at 230 nm was used for the quantitative determination.…”

Section: Guan Et Al (2000)mentioning

confidence: 99%

“…HPLC coupled with ultraviolet (UV) detection [12][13][14][15][16][17][18] , flourescence detection 19 , tandem mass spectrometry (MS-MS) [20][21][22][23] ; gas chromatography (GC) coupled with mass spectrometry (MS) 18,24 and capillary electrophoresis (CE) coupled with UV 6 are the reported methods that were used for determination of PTH in biological samples. In addition to that, colouremetric based determination methods 25 , radioimmunoassay 18 , enzyme immunoassay (EMIT) 18,26 , fluorescence polarization immunoassay (FPIA) 27 and spectrophotometric assay 18 have been often used monitorization of PHT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of phenytoin in human plasma by a validated hplc method: application to therapeutic drug monitoring study

Dural¹,

Bolayir²,

Çiğdem³

2021

actapharm

View full text Add to dashboard Cite

The aim of this study was to develop a simple and reliable HPLC method for the determination of phenytoin (PHT) in human plasma. Accuracy (RE%) were determined between (-0.93%) to 2.49% and precision (RSD%) values was ≤7.94. The quantitation limit was 3.54 μg/mL and recovery was found between 82.15% and 101.06%. The method was applied to real plasma samples (n = 7). Plasma-PHT levels were found between 1.12 and 18.76 μg/mL (9.52 ± 7.78, mean±SD). Both the plasma and dose-rated plasma results of PHT showed so high RSD% which were between 81.74% and 89.61%. In addition plasma-PHT levels were outside the recommended treatment range in 4 of the 7 patients (57.14%) examined, and also surprisingly PHT could not be detected in a patient's plasma. This procedure is relatively simple, precise, and applicable for routine therapeutic drug monitorization of PHT in neurology clinics or toxicological analyses in reference laboratories.

show abstract

Section: Guan Et Al (2000)mentioning

confidence: 99%